Why I'm Still Optimistic On LymPro And Amarantus Bio
- Last month Amarantus presented data on LymPro, the company's Alzheimer's disease blood test, at two Alzheimer's conferences.
- Amarantus shares ran up significantly in anticipation of this data, then corrected hard when the market was less than impressed with what was released.
- We believe the market may have misinterpreted the initial data on LymPro. Additional data, specifically with a newer version of the test, is coming in September 2014.
- Nothing we have seen over the past month changes our belief that the opportunity for Amarantus with LymPro, specifically under CLIA, remains meaningful.